Retail Investor
SanaCurrents subscribers receive a featured catalyst report every weekend, excluding four holidays.* The report is based on a score from a set of objective data points that establish the probability a biotech catalyst, such as a clinical trial result, will be positive. In our experience, a positive result typically increases the company’s share price. Historical results of SanaCurrents catalyst forecasts are displayed in the charts below.
Reports sent to retail subscribers include a sentiment rating, either a Superior, Pivotal or Advantageous. Superior is the highest sentiment rating. Superior and pivotal ratings reflect a probability score of at least 60%. See an example here.
Retail subscribers initially receive two free reports of pending catalysts, plus three new SanaCurrents reports following the start of a trial subscription. These five reports are archived individually on the SanaCurrents website for subscribers to track the progress and updates of catalysts as they advance and are realized during the year.
Subscribers also will receive periodic On the Horizon catalyst forecasts. The catalysts generally received a 45% to 55% probability score because supporting data from clinical studies is very early and/or inconsistent. The market response to even modest clinical progress, however, could trigger a significant increase in the stock price. Examples would include clinical progress in stopping the spread of Sars-CoV-2 or a new approach to treating Alzheimer’s disease.
*Holidays: Easter, July 4, US Thanksgiving and Christmas